Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose-derived allogeneic mesenchymal stem cell therapy - Steminent Biotherapeutics

Next Previous
Drug Profile

Adipose-derived allogeneic mesenchymal stem cell therapy - Steminent Biotherapeutics

Alternative Names: Adipose-derived allogeneic mesenchymal stem cells - Steminent; Allogeneic adipose-derived mesenchymal stem cells - Steminent Biotherapeutics; Mesenchymal stem cells - Steminent; Stemchymal®

Latest Information Update: 29 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Steminent Biotherapeutics
  • Developer ReproCELL; Steminent Biotherapeutics
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar ataxias; Ataxia
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Spinocerebellar ataxias
  • Phase II Ataxia
  • No development reported Liver failure

Most Recent Events

  • 24 Jun 2026 Preregistration for Spinocerebellar ataxias in Japan (IV)
  • 24 Jun 2026 Ministry of Health, Labour and Welfare grants Stemchymal® priority review for Stemchymal® for the treatment of Spinocerebellar ataxia
  • 24 Apr 2025 Steminent Biotherapeutics has patent protection for a mechanism of Stemchymal® in USA, prior to April 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top